George Budwell
George Budwell, PhD, is a contributing Motley Fool biotechnology and technology analyst covering disruptive innovators in healthcare, defense, and artificial intelligence. He also writes on portfolio theory, dividend stocks, and value investing. Prior to The Motley Fool, George was a freelance medical and science writer and a consultant for several life sciences hedge funds. Earlier in his career, he was an evolutionary biologist and completed postdoctoral fellowships at Kyoto University and Illinois State University. He holds a doctorate in evolutionary biology from Tulane University and a bachelor’s degree from Loyola University.
Recent Articles by George Budwell

Is D-Wave Quantum Stock Still a Buy?

2 eVTOL Stocks to Load Up On This Week

10 AI Stocks I'd Buy Without Hesitation

Is Nvidia Stock a Bargain?

2 No-Brainer Growth Stocks to Buy in June

3 Best Growth Stocks to Buy in June

Why I Own These 9 Vanguard ETFs

Is Amgen Stock a Buy?

2 AI Stocks to Buy Hand Over Fist Right Now

Is CoreWeave Stock Still a Buy After Its 200% Rally?

8 Quantum Computing Stocks to Buy Now

7 Artificial Intelligence (AI) Stocks to Buy Right Now

Why I'm Not Selling Archer Aviation Stock

2 Incredible Dividend Growth Stocks to Buy Now

3 Unstoppable Tech Stocks to Buy Hand Over Fist

1 Vanguard ETF Every Investor Should Consider
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.